Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

3.010 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Chromadex Corp CS

ChromaDex Corporation Reports Third Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021. 
From Business Wire News Releases
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen... 
From Business Wire News Releases
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The... 
From Business Wire News Releases
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Health, Inc. (“Elysium”) breached its contract... 
From Business Wire News Releases
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland... 
From Business Wire News Releases
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide... 
From Business Wire News Releases
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: 
From Business Wire News Releases
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021. 
From Business Wire News Releases
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. The... 
From Business Wire News Releases
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient. 
From Business Wire News Releases
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across the United States. Walmart is the first major U.S.... 
From Business Wire News Releases
ChromaDex Corporation Reports First Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. 
From Business Wire News Releases
ChromaDex and Ro Partner for New Product Development
ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to... 
From Business Wire News Releases
ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET (8:30am PT). ChromaDex CEO, Rob Fried,... 
From Business Wire News Releases
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021. The... 
From Business Wire News Releases
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in premium health, human and pet nutrition and personal... 
From Business Wire News Releases
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. 
From Business Wire News Releases
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare... 
From Business Wire News Releases
ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021... 
From Business Wire News Releases
ChromaDex to Present at the Zooming with LD Virtual Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor... 
From Business Wire News Releases
ChromaDex Corporation Reports 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results. 
From Business Wire News Releases
ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States... 
From Business Wire News Releases
ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT). 
From Business Wire News Releases
ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board
ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention... 
From Business Wire News Releases
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint... 
From Business Wire News Releases
ChromaDex Announces $25 Million Private Placement of Common Stock
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement... 
From Business Wire News Releases
ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2020. The... 
From Business Wire News Releases
New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press... 
From Business Wire News Releases
ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This... 
From Business Wire News Releases
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its potential to increase milk production among preterm... 
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.